Doctors Revision

Infectious Diseases

COVID-19 Disease

Infectious disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Spectrum ranges from asymptomatic infection to severe respiratory failure, multi-organ dysfunction, and death.

Also known as: Coronavirus Disease 2019

Open in the interactive guide
On this page

Referral and warning signs

When to refer

Refer to Hospital (H/RR) if: Signs of severe disease (dyspnea, hypoxia SpO2<90-94%, tachypnea RR>30), Danger signs (altered mental state, chest pain, inability to stay awake), High risk for progression with worsening symptoms. Requires oxygen therapy or advanced supportive care.

Red flags

  • Difficulty breathing / Shortness of breath at rest.
  • Oxygen saturation < 90-94% on room air.
  • Chest pain or pressure.
  • Confusion or inability to wake/stay awake.
  • Bluish lips or face (cyanosis).

Signs and symptoms

  • Highly variable, many asymptomatic.
  • Common symptoms: Fever or chills, Cough (usually dry), Fatigue/Malaise, Myalgia (muscle aches), Headache, Sore throat, Loss of taste or smell (anosmia/ageusia - quite specific).
  • Less common: Shortness of breath (dyspnea), Nasal congestion/rhinorrhoea, Nausea/vomiting, Diarrhoea.
  • Severe Disease: Severe dyspnea, Hypoxia (SpO2 <90-94% on room air), Tachypnea (RR >30/min), Lung infiltrates on imaging (>50%).
  • Critical Disease: Respiratory failure requiring mechanical ventilation, Septic shock, Multi-organ failure (ARDS, AKI, cardiac injury, coagulopathy, CNS involvement).
  • Post-COVID Conditions ('Long COVID'): Persistent symptoms (fatigue, dyspnea, cognitive issues, etc.) weeks or months after initial infection.

Risk factors

  • For Severe Disease:
  • - Older age (>60-65 years).
  • - Underlying chronic conditions: Cardiovascular disease (hypertension, heart failure, CAD), Diabetes, Chronic lung disease (COPD, moderate-severe asthma), Chronic kidney disease, Chronic liver disease, Obesity (BMI >30-40), Cancer, Immunocompromised state (HIV, transplant, immunosuppressive meds), Sickle cell disease.
  • - Smoking.
  • - Pregnancy.
  • - Unvaccinated status.

Diagnosis

Clinical assessment

Suspicion based on compatible symptoms +/- exposure history during periods of community transmission. Classification into Mild, Moderate, Severe, Critical based on clinical parameters (respiratory rate, SpO2, organ dysfunction).

Differential diagnosis

  • Seasonal Influenza / Other respiratory viruses (RSV, Rhinovirus, Adenovirus).
  • Bacterial pneumonia.
  • Malaria.
  • Typhoid fever.
  • Other causes of fever, cough, dyspnea.

Investigations

  • Nucleic Acid Amplification Tests (NAAT / RT-PCR): Gold standard for diagnosis. Detects viral RNA. Usually from nasopharyngeal/oropharyngeal swab.
  • Antigen Rapid Diagnostic Tests (Ag-RDT): Detect viral proteins. Faster, less expensive, good specificity but lower sensitivity than PCR (esp. early/late infection or low viral load). Useful for screening/initial diagnosis.
  • For Assessing Severity/Complications (Hospitalized patients):
  • - Pulse Oximetry (SpO2).
  • - Chest X-ray or CT Chest (shows ground-glass opacities, consolidation).
  • - Arterial Blood Gas (ABG).
  • - FBC (lymphopenia common), LFTs, Renal function, Electrolytes.
  • - Inflammatory markers (CRP, Ferritin, LDH, D-dimer - often elevated in severe disease).
  • - Coagulation studies.
  • - ECG, Troponin (if cardiac involvement suspected).

Diagnostic criteria

Laboratory confirmation (PCR or Antigen RDT) OR Clinical diagnosis based on symptoms/exposure during high prevalence periods.

Management

Non-pharmacological management

  • IPC Measures: Strict adherence by HCWs (Standard + Contact + Droplet precautions +/- Airborne for AGPs). Patient masking. Hand hygiene.
  • Isolation: Isolate suspected/confirmed cases (home isolation if mild/stable and feasible, hospital isolation otherwise).
  • Supportive Care:
  • - Rest, hydration, nutrition.
  • - Oxygen therapy (nasal cannula, mask, high-flow nasal cannula - HFNC, non-invasive ventilation - NIV) titrated to maintain SpO2 target (e.g., 90-94%).
  • - Prone positioning for moderate/severe ARDS.
  • - Mechanical ventilation for respiratory failure.
  • - Management of shock, AKI, secondary infections, thromboembolism.

Pharmacological treatment

  • Mild-Moderate Disease (Outpatient/Home - Low risk):
  • - Symptomatic treatment: Paracetamol/NSAIDs for fever/pain. Cough suppressants.
  • - Monitor for worsening symptoms/danger signs.
  • Mild-Moderate Disease (Outpatient - High risk for progression): (Consider antiviral therapy - specialist/guideline directed, start ASAP within 5-7 days of onset)
  • - Nirmatrelvir/Ritonavir (Paxlovid) PO for 5 days.
  • - Remdesivir IV for 3 days.
  • - Molnupiravir PO for 5 days (use only if others unavailable/contraindicated, C/I in pregnancy/breastfeeding).
  • Severe/Critical Disease (Hospitalized - Hypoxic): (LOC: RR)
  • - Oxygen Therapy (as above).
  • - Corticosteroids: Dexamethasone 6mg IV/PO daily for up to 10 days (or equivalent steroid). Reduces mortality in hypoxic patients.
  • - Anticoagulation: Prophylactic dose LMWH/Heparin recommended for all hospitalized patients (therapeutic dose if VTE present).
  • - Immunomodulators (if rapidly worsening/high inflammation):
  • - IL-6 Receptor Blockers (Tocilizumab or Sarilumab) IV single dose.
  • - OR JAK Inhibitor (Baricitinib) PO daily.
  • - Usually given in addition to dexamethasone.
  • - Antivirals (Remdesivir): May be considered early in hospitalization for severe disease (benefit debated, may shorten recovery time).
  • - Treat secondary bacterial infections if suspected.

Monitoring

Outpatient: Monitor symptoms, SpO2 if possible, advise on danger signs. Hospitalized: Continuous SpO2, vital signs, respiratory status. Monitor inflammatory markers, organ function. Monitor for complications (VTE, secondary infections).

Complications

  • Pneumonia, ARDS, Respiratory failure.
  • Sepsis, Septic shock.
  • Thromboembolism (DVT, PE, stroke, MI).
  • Acute Kidney Injury (AKI).
  • Cardiac injury (myocarditis, arrhythmia, heart failure).
  • Neurological complications (stroke, encephalopathy, Guillain-Barré).
  • Multisystem Inflammatory Syndrome in Children (MIS-C) and Adults (MIS-A).
  • Secondary bacterial/fungal infections.
  • Post-COVID Conditions ('Long COVID').

Prevention

  • Vaccination: Highly effective at preventing severe disease, hospitalization, and death. Primary series + Boosters as recommended.
  • IPC Measures: Mask wearing (especially indoors/crowded spaces), Hand hygiene, Physical distancing, Ventilation.
  • Testing and Isolation of cases.
  • Quarantine of contacts (per local guidelines).
  • Avoidance of crowded, poorly ventilated settings.

Patient education

  • Nature of COVID-19 illness.
  • How it spreads.
  • Importance of isolation.
  • Symptomatic management at home.
  • Danger signs requiring immediate medical attention.
  • Importance of vaccination.
  • Prevention measures (masks, hygiene, ventilation).

Uganda-specific notes

Management follows WHO and national MOH guidelines, which evolve. Access to specific antivirals (Paxlovid, Remdesivir), immunomodulators (Tocilizumab), critical care (oxygen, ventilation, ICU) is limited, especially outside major centres. Vaccination campaigns ongoing. Emphasis on prevention, early identification of severe disease, and supportive care.

References

  • Uganda Clinical Guidelines (UCG) 2023

    Chapter 2, Section 2.3.7

  • Ministry of Health, Uganda - Comprehensive COVID-19 Case Management Guidelines

    (Refer to latest version)

Scroll to Top